In a patient on fludrocortisone therapy, when should blood pressure be rechecked after dose reduction to determine if an antihypertensive medication should be added?

Blood Pressure Monitoring After Fludrocortisone Dose Reduction

Blood pressure should be rechecked within several days after reducing the fludrocortisone dose, as hypertension typically subsides within this timeframe; if blood pressure remains elevated after dose reduction and clinical reassessment, then initiate antihypertensive therapy while continuing the reduced fludrocortisone dose. 1, 2

Immediate Management Algorithm

When hypertension develops on fludrocortisone:

1. First step: Reduce fludrocortisone dose (typically from 0.1 mg to 0.05 mg daily) 1, 2

2. Recheck blood pressure within several days - The FDA label and clinical evidence indicate that signs of fludrocortisone overdosage (including hypertension) usually subside "within several days" after dose reduction 2

3. Clinical assessment during this period should include:

   • Sitting and standing blood pressure measurements
   • Assessment for peripheral edema
   • Evaluation for salt craving or postural light-headedness
   • Serum electrolytes (particularly potassium) 1

Decision Point for Adding Antihypertensives

If blood pressure remains uncontrolled after the dose reduction and several-day observation period, initiate antihypertensive treatment while continuing the reduced fludrocortisone dose. 1

Critical Considerations Before Adding Antihypertensives

Before concluding that antihypertensive medication is needed, verify:

• Glucocorticoid dose is not excessive - Overtreatment with either hydrocortisone/cortisone OR fludrocortisone can cause hypertension 1
• Patient is euvolemic - Assess for volume overload through clinical examination
• No interfering substances - Licorice and grapefruit juice potentiate mineralocorticoid effects and should be avoided 1

Preferred Antihypertensive Agents

If antihypertensive therapy becomes necessary after fludrocortisone dose optimization:

• First-line: Angiotensin II receptor blockers (ARBs) or ACE inhibitors - these counter the vasoconstrictive effects of elevated angiotensin II 1
• Second-line: Dihydropyridine calcium channel blockers 1
• Contraindicated: Aldosterone receptor blockers (spironolactone, eplerenone) and diuretics should be avoided 1

Common Pitfalls

• Don't wait too long: The "several days" timeframe from the FDA label 2 provides clear guidance - prolonged observation without reassessment risks either undertreating hypertension or missing the need for medication adjustment

• Don't assume primary hypertension immediately: Primary hypertension can coexist with adrenal insufficiency 1, but medication-induced hypertension from fludrocortisone or glucocorticoid overreplacement must be excluded first through dose optimization

• Don't use plasma renin or ACTH to guide this decision: While plasma renin activity in the upper reference range indicates adequate mineralocorticoid dosing 1, blood pressure control is assessed clinically, not biochemically